SEARL Stock Overview
Manufactures and sells pharmaceutical and other consumer products in Pakistan, Sri Lanka, Cambodia, Myanmar, Vietnam, Oman, Laos, Kenya, Yemen, Tajikistan, Uganda, the Philippines, Rwanda, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
The Searle Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨82.44 |
| 52 Week High | PK₨89.45 |
| 52 Week Low | PK₨43.03 |
| Beta | 0.74 |
| 11 Month Change | 34.62% |
| 3 Month Change | 38.48% |
| 1 Year Change | 39.85% |
| 33 Year Change | -25.42% |
| 5 Year Change | -26.63% |
| Change since IPO | 2,050.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| SEARL | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | -2.0% | 1.9% | 2.1% |
| 1Y | 39.8% | 126.5% | 43.4% |
Return vs Industry: SEARL underperformed the PK Pharmaceuticals industry which returned 126.5% over the past year.
Return vs Market: SEARL underperformed the PK Market which returned 43.4% over the past year.
Price Volatility
| SEARL volatility | |
|---|---|
| SEARL Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in PK Market | 9.6% |
| 10% least volatile stocks in PK Market | 3.8% |
Stable Share Price: SEARL has not had significant price volatility in the past 3 months compared to the PK market.
Volatility Over Time: SEARL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 4,026 | Syed Ahmed | searlecompany.com |
The Searle Company Limited, together with its subsidiaries, manufactures and sells pharmaceutical and other consumer products in Pakistan, Sri Lanka, Cambodia, Myanmar, Vietnam, Oman, Laos, Kenya, Yemen, Tajikistan, Uganda, the Philippines, Rwanda, and internationally. The company offers pharmaceutical products, such as analgesics and muscle relaxants, anti-allergy and anti-tussive, anti-anemic, anti-chelating, anti-infective, anti-neoplastic, anti-thrombotic, cardiovascular, endocrinology and metabolism, gastrointestinal, gynecology, urology and sex hormones, hepatology, hospital solutions, neurology and psychiatry, orthopedics and rheumatology, respiratory, and systemic-hormones. It also provides biopharmaceutical products; nutraceutical products, such as herbal supplements, probiotics and enzymes, and vitamins and minerals; nutrition products, including baby cereals; consumer products; consumer products; and medical devices and disposables for blood transfusion, critical care and anesthesia, IV administration, ophthalmology, and renal care, as well as surgical gloves.
The Searle Company Limited Fundamentals Summary
| SEARL fundamental statistics | |
|---|---|
| Market cap | PK₨42.46b |
| Earnings (TTM) | PK₨983.31m |
| Revenue (TTM) | PK₨28.32b |
42.9x
P/E Ratio1.5x
P/S RatioIs SEARL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEARL income statement (TTM) | |
|---|---|
| Revenue | PK₨28.32b |
| Cost of Revenue | PK₨15.28b |
| Gross Profit | PK₨13.04b |
| Other Expenses | PK₨12.06b |
| Earnings | PK₨983.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.92 |
| Gross Margin | 46.05% |
| Net Profit Margin | 3.47% |
| Debt/Equity Ratio | 38.4% |
How did SEARL perform over the long term?
See historical performance and comparison